Hudson’s Bay Co (HBC) EPS Estimated At $-0.58; Aerie Pharmaceuticals (AERI) Had 14 Bullish Analysts

November 15, 2017 - By Vivian Park

Among 14 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 41 analyst reports since August 7, 2015 according

to SRatingsIntel. The firm earned “Buy” rating on Monday, October 16 by Canaccord Genuity. The firm earned “Outperform” rating on Wednesday, November 4 by RBC Capital Markets. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 20. The firm has “Buy” rating given on Tuesday, August 1 by Canaccord Genuity. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) has “Outperform” rating given on Thursday, September 15 by RBC Capital Markets. The firm earned “Buy” rating on Thursday, July 20 by Cantor Fitzgerald. The firm earned “Buy” rating on Friday, August 7 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, September 15. As per Friday, September 15, the company rating was maintained by Needham. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, October 11 report. See Aerie Pharmaceuticals Inc (NASDAQ:AERI) latest ratings:

09/11/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0 Maintain
24/10/2017 Broker: Guggenheim Rating: Buy New Target: $80 Initiates Coverage On
16/10/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $65 New Target: $73 Maintain
11/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $70.0 Maintain
11/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $62.0 Maintain
05/10/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0 Maintain
26/09/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0 Maintain
22/09/2017 Broker: JMP Securities Rating: Buy New Target: $68.0 Maintain
20/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $65.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $65.0 Maintain

Analysts expect Hudson’s Bay Co (TSE:HBC) to report $-0.58 EPS on December, 4.They anticipate $0.02 EPS change or 3.57% from last quarter’s $-0.56 EPS. After having $-0.90 EPS previously, Hudson’s Bay Co’s analysts see -35.56% EPS growth. The stock decreased 2.55% or $0.3 on November 14, reaching $11.45. About 294,580 shares traded. Hudson’s Bay Co (TSE:HBC) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 8 analysts covering Hudson’s Bay Company (TSE:HBC), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Hudson’s Bay Company had 43 analyst reports since September 11, 2015 according to SRatingsIntel. On Wednesday, April 5 the stock rating was maintained by Scotia Capital with “Sector Perform”. The stock has “Buy” rating by TD Securities on Tuesday, August 30. On Friday, January 8 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm earned “Outperform” rating on Friday, June 10 by Scotia Capital. The stock of Hudson’s Bay Co (TSE:HBC) has “Sector Perform” rating given on Wednesday, March 29 by RBC Capital Markets. BMO Capital Markets maintained the shares of HBC in report on Tuesday, May 23 with “Outperform” rating. RBC Capital Markets maintained Hudson’s Bay Co (TSE:HBC) on Monday, November 30 with “Outperform” rating. The rating was downgraded by Credit Suisse on Friday, April 21 to “Neutral”. The firm has “Sector Perform” rating by Scotia Capital given on Friday, February 24. The rating was maintained by Scotia Capital with “Sector Perform” on Friday, March 24.

Hudson’s Bay Company is a Canada department store retailer. The company has market cap of $2.09 billion. The Firm is an operator and a consolidator, as well as a real estate developer. It currently has negative earnings. The Company’s retail portfolio includes approximately 10 banners, in formats ranging from luxury to better department stores to off price fashion shopping destinations, with over 460 stores.

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $2.22 billion. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It currently has negative earnings. The Company’s product candidates include Rhopressa 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

The stock decreased 2.88% or $1.8 during the last trading session, reaching $60.6. About shares traded. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since November 15, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Since May 26, 2017, it had 0 insider buys, and 1 insider sale for $1.12 million activity. Foresite Capital Management II – LLC had sold 20,000 shares worth $1.12 million.

Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.21, from 0.96 in 2017Q1. It is positive, as 21 investors sold Aerie Pharmaceuticals Inc shares while 48 reduced holdings. 33 funds opened positions while 48 raised stakes. 31.61 million shares or 3.55% more from 30.53 million shares in 2017Q1 were reported. Prudential Fin reported 82,590 shares. Boothbay Fund Management Ltd Liability Corp has invested 0.09% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Aqr Capital Ltd Liability holds 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 34,621 shares. Kazazian Asset Ltd Liability Corp holds 8,558 shares. Ubs Asset Mngmt Americas holds 17,161 shares or 0% of its portfolio. Hudson Bay Cap Mngmt L P holds 0.04% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 40,000 shares. Envestnet Asset Mgmt holds 414 shares or 0% of its portfolio. Moreover, Amalgamated Bancshares has 0.01% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 3,887 shares. 377,384 were reported by Alliancebernstein L P. State Street Corp holds 701,525 shares or 0% of its portfolio. Voloridge Inv Management Ltd Liability Company accumulated 72,947 shares. Ameritas Investment Prns Incorporated reported 0.01% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). 188 are owned by Oppenheimer Asset Management Inc. Neuberger Berman Gru Lc has 12,500 shares for 0% of their portfolio. 3.45 million are owned by Adage Cap Partners Group Incorporated Ltd Liability.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>